Ekpe Etoroabasi, Shaikh Asim Jamal, Shah Jasmit, Jacobson Judith S, Sayed Shahin
Columbia University Vagelos College of Physicians and Surgeons, New York, NY.
Columbia University Mailman School of Public Health, New York, NY.
J Glob Oncol. 2019 Jul;5:1-11. doi: 10.1200/JGO.19.00036.
The purpose of this research was to describe the sociodemographic and clinical characteristics of Kenyan women with metastatic breast cancer diagnosed and treated at Aga Khan University Hospital in Nairobi, Kenya from 2012 to 2018.
We reviewed charts of Kenyan women with metastatic breast cancer and analyzed sociodemographic data, breast cancer risk factors, and tumor characteristics associated with stage at diagnosis, receptor status (ie, estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 [HER2]), and site of metastasis using χ, analysis of variance, two-sample tests, and logistic regressions.
A total of 125 cases with complete medical records were included in the analysis. Forty women (32%) had metastases at diagnosis. Of the others, those diagnosed in stage III developed metastases sooner than those diagnosed in stage II ( < .001). Fifty-eight percent of patients had metastases to bone, 14% to brain, 57% to lungs, and 50% to liver. Seventy-four percent of patients presented with more than one metastatic site. Metastases to bone were associated with greater age at diagnosis ( = .02) and higher parity ( = .04), and metastases to the brain were associated with early menopause ( = .04), lower parity ( = .04), and lack of breastfeeding ( = .01). Patients whose tumors were triple negative (estrogen receptor-negative, progesterone receptor-negative, and HER2 negative) were more likely to develop brain metastases ( = .01), and those whose tumors were HER2 positive were more likely to develop liver metastases ( = .04).
Although our data on patterns of metastases and pathologic subtypes are similar to those in published literature, some unique findings concerning hormonal risk factors of women with metastatic breast cancer and specific metastatic sites need additional exploration in larger patient populations.
本研究旨在描述2012年至2018年在肯尼亚内罗毕阿迦汗大学医院诊断和治疗的转移性乳腺癌肯尼亚女性的社会人口统计学和临床特征。
我们回顾了转移性乳腺癌肯尼亚女性的病历,并使用χ检验、方差分析、双样本检验和逻辑回归分析了社会人口统计学数据、乳腺癌危险因素以及与诊断分期、受体状态(即雌激素受体、孕激素受体和人表皮生长因子受体2[HER2])和转移部位相关的肿瘤特征。
共有125例有完整病历的患者纳入分析。40名女性(32%)在诊断时已有转移。在其他患者中,III期诊断的患者比II期诊断的患者更早发生转移(P<0.001)。58%的患者发生骨转移,14%发生脑转移,57%发生肺转移,50%发生肝转移。74%的患者有不止一个转移部位。骨转移与诊断时年龄较大(P=0.02)和较高的产次(P=0.04)相关,脑转移与早绝经(P=0.04)、较低的产次(P=0.04)和未母乳喂养(P=0.01)相关。肿瘤为三阴性(雌激素受体阴性、孕激素受体阴性和HER2阴性)的患者更易发生脑转移(P=0.01),而肿瘤为HER2阳性的患者更易发生肝转移(P=0.04)。
尽管我们关于转移模式和病理亚型的数据与已发表文献中的数据相似,但关于转移性乳腺癌女性激素危险因素和特定转移部位的一些独特发现需要在更大的患者群体中进一步探索。